Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

What 8% Emerging Markets Growth Means for Reckitt (LSE:RKT) as the FTSE 100 Group Resets

Plus 8.0%, plus 0.8%, minus 1.3%. Those three numbers capture the uneven shape of Reckitt's (LSE:RKT) third quarter. Emerging Markets revenue rose 8.0% on a like-for-like basis to £1.17bn, Europe grew 0.8% to £867m, and North America fell 1.3% to £649m. Together the three …

Ankur Sharma | 28 October 2026

Why Reckitt's (LSE:RKT) 19 November New Jersey Event Now Matters to FTSE 100 Investors

Investor events are usually planned long in advance, and their importance can shift with circumstances. Reckitt's (LSE:RKT) North America event, scheduled for Thursday 19 November 2026 at its New Jersey headquarters, is a case in point. When the company published its third-quarter trading update …

Ankur Sharma | 28 October 2026

Hikma Pharmaceuticals Dips: Can the Generic Drug Giant Sustain Its Global Growth Momentum?

Hikma's business model spans three main divisions: the US injectables business, which is the largest profit contributor and focuses on complex sterile generic injectables for hospital and acute care settings; the branded pharmaceuticals business, which sells branded medicines across MENA markets; and the generics …

Divya Sood | 28 October 2026

CVS Group Edges Lower: Is the Veterinary Consolidator Keeping Pace With Rising Pet Healthcare Demand?

CVS's business model is based on the acquisition and integration of independent veterinary practices into a professionally managed group, while retaining the clinical independence and local identity of individual practices. The company generates revenue from primary care consultations, diagnostic services, prescriptions, surgical procedures and …

Divya Sood | 28 October 2026

What Comes Next for Oxford Nanopore Technologies Plc as Investors Reassess the Outlook (ONT)

Oxford Nanopore Technologies Plc (LSE:ONT) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Investors are tracking sequencing-platform …

Ankur Sharma | 28 October 2026

What Comes Next for Eden Biosolutions PLC as Investors Reassess the Outlook (EDEN)

Eden Biosolutions PLC (LSE:EDEN) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Recent company attention follows its …

Ankur Sharma | 28 October 2026

What Inspiration Healthcare’s Interim Results Signal About Demand (IHC)

Inspiration Healthcare Group PLC (LSE:IHC) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: Interim results have focused …

Ankur Sharma | 28 October 2026

What Comes Next for ImmuPharma plc as Investors Reassess the Outlook (IMM)

ImmuPharma plc (LSE:IMM) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: The clinical-stage biotechnology company is in …

Ankur Sharma | 28 October 2026

What Comes Next for IXICO Plc as Investors Reassess the Outlook (IXI)

IXICO Plc (LSE:IXI) is in focus as investors assess the company’s latest operating context, its near-term catalysts and the evidence needed to support its longer-term strategy. As of 27 October 2026, the most relevant company-specific angle is this: The clinical-trial technology group is being …

Ankur Sharma | 28 October 2026

SkinBioTherapeutics Plc (LSE:SBTX) in Focus: What the AIM Market Is Watching After 27 October 2026

SkinBioTherapeutics Plc (LSE:SBTX) attracts attention through its exposure to skin microbiome research and commercial skincare.

Ankur Sharma | 28 October 2026
Support

Hi! How can we help you today?

Loading…